Somatropin (rhGH)
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Somatropin (rhGH) is listed as gh axis / recombinant hormone.
- •Growth hormone deficiency
- •Short stature
- •HIV wasting
- •Off-label body composition / performance
Regulatory status: FDA-Approved Rx; non-medical use prohibited and WADA-banned.
Structure & Properties
Compound: Somatropin (rhGH); also known as Genotropin, Norditropin, Humatrope, HGH.
Pharmacologic class: GH Axis / Recombinant Hormone.
Known delivery routes: Subcutaneous, Intramuscular.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Recombinant 191-amino-acid human growth hormone; binds GH receptor to drive hepatic IGF-1 output, lipolysis, and nitrogen retention.
- •Increased lean mass and reduced visceral fat
- •Improved recovery and connective tissue turnover
- •Normalizes IGF-1 in true deficiency
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Extensively studied in GHD; performance use not approved.
Laboratory Research
Extensively studied in GHD; performance use not approved
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No strict time-of-day requirement. Dose consistently at the same time daily and rotate injection sites. Follow the per-peptide dosing section above.
Potential interactions and combinations to avoid
- •Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- •Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Insulin resistance / hyperglycemia
- •Carpal tunnel, edema, arthralgia
- •Cardiac and organ hypertrophy with supraphysiologic use
- •Possible tumor growth promotion
Contraindications
- •Active malignancy
- •Proliferative diabetic retinopathy
- •Acute critical illness
- •Closed epiphyses with non-approved indication
- •Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- •Active or untreated diabetic retinopathy
- •Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- •Untreated hypothyroidism or uncorrected adrenal insufficiency
- •Acromegaly, pituitary adenoma, or intracranial hypertension
- •Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- •Critical illness after acute surgery, trauma, or respiratory failure
- •Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Prader-Willi syndrome with severe obesity or respiratory impairment
- •Closed epiphyses when used for height indications
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 0.15–0.6 mg/day (clinical); off-label performance use commonly 1–4 IU/day
Frequency: Daily, usually evening
Cycling: Clinical use is continuous with IGF-1 monitoring. Non-medical protocols often cycle 8–16 weeks, which does not remove metabolic risk.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Intramuscular (IM)
Used for depot formulations, some GH secretagogues (localized delivery), and clinical protocols requiring faster systemic uptake.
23–25G × 1–1.5" needle. 1–3 mL syringe. Ventrogluteal, vastus lateralis, or deltoid. Insert 90°, aspirate (optional), inject slowly. Rotate sites weekly.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Somatropin (rhGH)?
In plain words
Somatropin is a lab-made version of human growth hormone. It signals the liver to make IGF-1 [a growth-promoting protein] and helps the body break down fat and retain nitrogen, a building block of proteins. It is studied and used medically for low growth hormone levels, short stature, and severe weight loss linked to HIV. Clinical trials support medical uses, but risks include high blood sugar, swelling, joint pain, and possible tumor growth; above-normal hormone levels can also enlarge the heart and other organs.
Technical definition
Somatropin (rhGH) is a recombinant human growth hormone consisting of 191 amino acids that binds the growth hormone receptor, stimulating hepatic IGF-1 production, lipolysis, and nitrogen retention. Phase III randomized controlled trial evidence supports its clinical use, with listed uses including growth hormone deficiency, short stature, and HIV wasting. It is an FDA-approved prescription drug; non-medical use is prohibited, and it is banned by WADA.
Function
Dosing
Recommended Time of Day
Before bed for anti-aging protocols; split morning/pre-bed at higher clinical doses.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- Ventrogluteal — Palm on greater trochanter, index to ASIS — inject in the V. Safest IM site.
- Dorsogluteal (upper outer) — Upper outer quadrant of the buttock. Used for depot IM; alternate sides each cycle.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
- Anterior thigh (vastus lateralis) — Middle third of the outer front thigh. Preferred IM site for self-injection.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Clinical use is continuous with IGF-1 monitoring. Non-medical protocols often cycle 8–16 weeks, which does not remove metabolic risk.
Timing & Interactions
- ·Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- ·Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
- ·Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Somatropin (rhGH) and sync them to Vial Lab.
Benefits
- ·Increased lean mass and reduced visceral fat
- ·Improved recovery and connective tissue turnover
- ·Normalizes IGF-1 in true deficiency
Risks
- ·Insulin resistance / hyperglycemia
- ·Carpal tunnel, edema, arthralgia
- ·Cardiac and organ hypertrophy with supraphysiologic use
- ·Possible tumor growth promotion
Contraindications
- ·Active malignancy
- ·Proliferative diabetic retinopathy
- ·Acute critical illness
- ·Closed epiphyses with non-approved indication
- ·Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- ·Active or untreated diabetic retinopathy
- ·Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- ·Untreated hypothyroidism or uncorrected adrenal insufficiency
- ·Acromegaly, pituitary adenoma, or intracranial hypertension
- ·Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- ·Critical illness after acute surgery, trauma, or respiratory failure
- ·Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Prader-Willi syndrome with severe obesity or respiratory impairment
- ·Closed epiphyses when used for height indications
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx; non-medical use prohibited and WADA-banned
Veterinary Use (Pets)
No established veterinary protocol for Somatropin (rhGH). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.